extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J
Search Results
Updates in the Treatment of Bone Cancer
J. Sybil Biermann
Melanoma
Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist
Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent
Long-Term Therapy of Venous Thromboembolism in Cancer Patients
Michael B. Streiff
adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group . J Clin Oncol 1996 ; 14 : 2731 – 2737 . 13. Holm T Singnomklao T Rutqvist LE Cedermark B . Adjuvant
Multimodality Approaches to Localized Gastric Cancer
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i
Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS
Hiram S. Cody III and Kimberly J. Van Zee
. AJCC Cancer Staging Manual ( Sixth Edition ). New York : Springer-Verlag , 2002 . 58 Ravdin PM Siminoff IA Harvey JA . Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy . J Clin Oncol
Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ
Stephen B. Edge and David G. Sheldon
cancer patients receiving no adjuvant therapy . J Clin Oncol 2001 ; 19 : 1468 – 1475 . 37 Gray RJ Cox CE Reintgen DS . Importance of missed axillary micrometastases in breast cancer patients . Breast J 2001 ; 7 : 303 – 307 . 38
Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials
David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman
Pritchard KI Paterson AHG Fine S . Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor
Opioid and Benzodiazepine Use in Women With Breast Cancer: More Work on the Horizon
Juan P. Cata and Daniel D. Kim
studies suggest that women aged ≥66 years present a high risk of developing prolonged use of opioids and benzodiazepines. Interestingly, Sakamoto et al 6 found that surgery combined with adjuvant therapies was an independent risk factor for new opioid and
Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
method of operation. However, this information is important to review postoperatively because it may better identify patients with aggressive pathologic features potentially suitable for adjuvant therapy clinical trials. The Role of Lymphadenectomy
Kidney Cancer
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
Elson P Propert K . Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract] . Proc Am Soc Clin Oncol 1996 ; 15 : Abstract 253 . 19 Kavolius JP
